Vigene Biosciences, a Charles River Company, is a leading supplier of gene delivery technologies within the pharmaceutical industry, specialising as a Contract Manufacturing Organisation (CMO) and Contract Development and Manufacturing Organisation (CDMO). Founded in 2012 by a team of scientists with extensive expertise in virology and gene therapy, Vigene is dedicated to advancing biomedical research and making gene therapy affordable. The company provides a range of research-grade and cGMP-grade products and custom services, focusing on viral vectors such as adenovirus, lentivirus, and adeno-associated virus (AAV).

Services include:
– Research-grade and cGMP-grade AAV products
– Research-grade and cGMP-grade lentivirus products
– Research-grade and cGMP-grade adenovirus products
– Custom viral vector development services
– Ready-to-ship genome-wide human cDNA ORFs on adenoviral or lentiviral vectors
– AAV shRNA constructs
– Pre-made control GFP viruses
– AAV biosensors developed in partnership with Janelia Research Campus
– AAV alpha-synuclein vectors developed in partnership with The Michael J Fox Foundation

As a prominent entity in the field, Vigene Biosciences, a Charles River Company, continues to innovate and support the advancement of gene therapy, encouraging those interested in their offerings to find more information at vigenebio.com.